New framework defines core competencies for contemporary brain brachytherapy
The framework emphasizes multidisciplinary selection, source geometry, imaging, postimplant dosimetry, QA and radiation safety for modern intracranial Cs-131 brachytherapy.
The framework emphasizes multidisciplinary selection, source geometry, imaging, postimplant dosimetry, QA and radiation safety for modern intracranial Cs-131 brachytherapy.
Patients reported greater symptom burden than clinicians in 84% of matched domains, with the largest gaps in psychological and less visible symptoms.
Across 14 studies, repeat stereotactic radiotherapy achieved 76% one-year local control, but symptomatic radiation necrosis occurred in 10%.
Adding functional brain regions to CyberKnife optimization reduced dose to multiple structures by roughly 23%–39% while preserving target coverage.
KRAS-mutant and wild-type NSCLC showed similar intracranial control after SRS, while higher radiation dose predicted better outcomes.
CyberKnife best contained low-dose spread at high lesion burdens but required substantially longer treatment than faster VMAT strategies.
SMART reduced mean memory-circuit dose from 2.9 to 1.8 Gy while maintaining greater than 95% target coverage.
Tumor volume and OAR proximity drove brain metastasis fractionation, while preoperative SRS showed a substantial preference-to-practice gap.
After propensity matching, SRT did not improve survival over WBRT, while adding a boost showed a non-robust intracranial control signal.
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
Synthetic CT reproduced CyberKnife target dosimetry closely and enabled submillimetre translational image guidance, although rotational errors were more variable.
Individual target optimization lowered normal-brain V12 and improved dose gradients while maintaining over 99% coverage, at the cost of higher monitor units.
Single-fraction 22 Gy SRS achieved higher one-year local control than 20 Gy, although retrospective dose selection creates important confounding.
A 1 mm symmetric MLC closing reduced minimum GTV dose by 25%, while translations caused cumulative target undercoverage.
Preoperative SRS/FSRT completed local therapy 22.5 days sooner than postoperative treatment, with similar 30-day morbidity; oncologic outcomes remain pending.